ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from ...
ATLANTA - Artivion, Inc. (NYSE:AORT), a $1.93 billion market cap medical device company whose shares have surged 31.86% over the past six months, announced new clinical data from two trials evaluating ...
1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical ...
At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
Investing.com - Barclays has maintained its Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a price target of $44.00, representing nearly 79% upside from the current price of $24.61.
ATLANTA, GA, UNITED STATES, January 13, 2026 / EINPresswire.com / — Enlighten Clinical Solutions today announced the official release of its integrated electronic Trial Master File (eTMF) module, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results